KFAS
PRQR icon

Keating Financial Advisory Services’s ProQR Therapeutics PRQR Stock Holding History

Keating Financial Advisory Services’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.3K Buy
20,552
+552
+3% +$905 0.01% 742
2025
Q4 		$40.4K Buy
+20,000
New +$46.7K 0.01% 703

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Keating Financial Advisory Services's PRQR Position: Q1 2026 in Review

Keating Financial Advisory Services increased its ProQR Therapeutics (PRQR) stake by 2.8% in Q1 2026, buying an estimated $905 and bringing the position to 20,552 shares worth $33.3K. The position accounts for 0.01% of the portfolio, ranked #742.

Keating Financial Advisory Services first reported a position in PRQR in Q4 2025 and has held it in 2 quarters since. The position peaked at $40.4K in Q4 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Keating Financial Advisory Services held 20,552 shares of ProQR Therapeutics worth $33.3K as of Q1 2026.
  • Keating Financial Advisory Services bought 552 ProQR Therapeutics shares in Q1 2026, an estimated $905.
  • ProQR Therapeutics made up 0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #742 holding.
  • Keating Financial Advisory Services first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's ProQR Therapeutics position peaked at $40.4K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.